相关实验视频

Updated: Jul 5, 2025

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

在寻找小分子抑制剂对抗hCA IX的过程中,基于联体的药模拟和集成的计算方法

Venkatesan Saravanan¹, Bharath Kumar Chagaleti¹, Shakthi Devi Packiapalavesam¹

¹Department of Pharmaceutical Chemistry, SRM College of Pharmacy, SRM Institute of Science and Technology Kattankulathur Chengalpattu 603203 India.

|January 23, 2024

概括

研究人员确定了碳酸酶IX (hCA IX) 的潜在选择性抑制剂,这是缺氧瘤的关键标. 计算方法选了天然化合物,揭示了对抗癌症的进一步实验验证有希望的候选人.

科学领域:

生物化学生化学
药用化学医学化学
计算生物学计算生物学

背景情况:

碳酸无水酶IX (hCA IX) 在缺氧瘤中过度表达,在pH调节和癌症进展中发挥作用.
选择性抑制hCA IX至关重要,以避免破坏其他碳酸酶异型并最大限度地降低毒性.
自然衍生物被探索为新型选择性hCA IX抑制剂的来源.

研究的目的:

开发一种针对选择性hCA IX抑制剂的药模型.
为了虚拟选数据库,寻找符合药理模型的自然化合物.
通过计算评估潜在的hCA IX抑制剂的结合亲和力和稳定性.

主要方法:

使用诱套件进行药模拟和验证.
复合数据库的虚拟选.
分子对接,分子动力学模拟 (100 ns) 和DFT研究.

主要成果:

确定了43个RMSD<1的初始结果,显示与关键残留物 (ZN301,HIS94,HIS96,HIS119) 的良好相互作用.
在分子动力学模拟中,前四种化合物表现出复杂的稳定性.
化合物的平均结合分数为 -7.8 Kcal mol-1 ,具有有利的 DFT 能量变化.

结论:

鉴定到的化合物显示出选择性hCA IX抑制的理论潜力.
需要进一步的实验研究来确认这些化合物的抑制作用和选择性.
这项研究为开发新的hCA IX向癌症疗法提供了强大的计算基础.

更多相关视频

Method for Identifying Small Molecule Inhibitors of the Protein-protein Interaction Between HCN1 and TRIP8b

Method for Identifying Small Molecule Inhibitors of the Protein-protein Interaction Between HCN1 and TRIP8b

Published on: November 11, 2016

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

相关概念视频

Ligand Binding Sites

Ligand Binding Sites

Proteins are dynamic macromolecules that carry out a wide variety of essential processes; however, the activities of most proteins depend on their interactions with other molecules or ions, known as ligands.
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...

Protein-protein Interfaces

Protein-protein Interfaces

Many proteins form complexes to carry out their functions, making protein-protein interactions (PPIs) essential for an organism's survival. Most PPIs are stabilized by numerous weak noncovalent chemical forces. The physical shape of the interfaces determines the way two proteins interact. Many globular proteins have closely-matching shapes on their surfaces, which form a large number of weak bonds. Additionally, many PPIs occur between two helices or between a surface cleft and a...

Drug Discovery: Overview

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...